XFOR

SEC source: 0001628280-24-042542 · wk-form4_1728420247.xml · nonDerivative · entry 2

DiBiase Mary · CIK 0001880179 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 452,060

F2 · shares: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.55 to $0.6043, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-24-042545 · wk-form4_1728420276.xml · nonDerivative · entry 2

Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · shares: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5144 to $0.6036, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-24-042544 · wk-form4_1728420266.xml · nonDerivative · entry 2

Baldry Mark · CIK 0001644137 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,509

F2 · shares: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.561 to $0.6115, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-24-042543 · wk-form4_1728420257.xml · nonDerivative · entry 2

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,057,713

F2 · shares: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5142 to $0.6036, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-24-042541 · wk-form4_1728420235.xml · nonDerivative · entry 2

Taveras Arthur · CIK 0001830901 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 388,026

F2 · shares: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5291 to $0.6038, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-24-042542 · wk-form4_1728420247.xml · nonDerivative · entry 1

DiBiase Mary · CIK 0001880179 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 519,755

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition.

SEC source: 0001628280-24-042545 · wk-form4_1728420276.xml · nonDerivative · entry 1

Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 230,645

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of the performance condition.

SEC source: 0001628280-24-042544 · wk-form4_1728420266.xml · nonDerivative · entry 1

Baldry Mark · CIK 0001644137 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,636

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition.

SEC source: 0001628280-24-042543 · wk-form4_1728420257.xml · nonDerivative · entry 1

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,297,149

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition.

SEC source: 0001628280-24-042541 · wk-form4_1728420235.xml · nonDerivative · entry 1

Taveras Arthur · CIK 0001830901 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 464,946

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition.

SEC source: 0001628280-24-040128 · wk-form4_1726084882.xml · nonDerivative · entry 1

DiBiase Mary · CIK 0001880179 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 289,110

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.6548 to $0.6646, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

SEC source: 0001628280-24-027671 · wk-form4_1718136724.xml · nonDerivative · entry 1

WYZGA MICHAEL S · CIK 0001201256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,667

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-24-027676 · wk-form4_1718136785.xml · nonDerivative · entry 1

MCGIRR DAVID W J · CIK 0001219023 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,667

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-24-027678 · wk-form4_1718136807.xml · nonDerivative · entry 1

de Craecker Francoise · CIK 0001887843 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,667

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-24-027677 · wk-form4_1718136796.xml · nonDerivative · entry 1

Aliski William · CIK 0001598426 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,667

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-24-027675 · wk-form4_1718136772.xml · nonDerivative · entry 1

Stewart Murray · CIK 0001723450 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,504

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-24-027674 · wk-form4_1718136760.xml · nonDerivative · entry 1

Bridger Gary · CIK 0001600049 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,667

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-24-027673 · wk-form4_1718136748.xml · nonDerivative · entry 1

Woods Keith · CIK 0001996804 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-24-027672 · wk-form4_1718136736.xml · nonDerivative · entry 1

Lawton Alison Frances · CIK 0001542650 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,667

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-25-005698 · wk-form4_1739567298.xml · nonDerivative · entry 1

Baldry Mark · CIK 0001644137 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,769

F1 · balance_after: The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported.

SEC source: 0001628280-24-010278 · wk-form4_1710191967.xml · nonDerivative · entry 1

DiBiase Mary · CIK 0001880179 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 291,752

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.91, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

SEC source: 0001628280-24-010279 · wk-form4_1710191979.xml · nonDerivative · entry 1

Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.8649 to $0.9147, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-24-010281 · wk-form4_1710192010.xml · nonDerivative · entry 1

Taveras Arthur · CIK 0001830901 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 234,301

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.9112, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

SEC source: 0001628280-24-010280 · wk-form4_1710191995.xml · nonDerivative · entry 1

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 765,068

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.9147, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award

SEC source: 0001628280-24-005383 · wk-form4_1708121369.xml · derivative · entry 1

DiBiase Mary · CIK 0001880179 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 428,248

Underlying: Common Stock · 428,248 shares

Expires 2034-02-13

F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.

SEC source: 0001628280-24-005384 · wk-form4_1708121388.xml · derivative · entry 1

Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 523,414

Underlying: Common Stock · 523,414 shares

Expires 2034-02-13

F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.

SEC source: 0001628280-24-005385 · wk-form4_1708121451.xml · derivative · entry 1

Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 475,831

Underlying: Common Stock · 475,831 shares

Expires 2034-02-13

F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.

SEC source: 0001628280-24-005382 · wk-form4_1708121356.xml · derivative · entry 1

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,189,578

Underlying: Common Stock · 1,189,578 shares

Expires 2034-02-13

F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.

SEC source: 0001628280-24-005380 · wk-form4_1708121338.xml · derivative · entry 1

Baldry Mark · CIK 0001644137 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 523,414

Underlying: Common Stock · 523,414 shares

Expires 2034-02-13

F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.

SEC source: 0001628280-24-005379 · wk-form4_1708121312.xml · derivative · entry 1

Taveras Arthur · CIK 0001830901 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 428,248

Underlying: Common Stock · 428,248 shares

Expires 2034-02-13

F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.

SEC source: 0001628280-24-007711 · wk-form4a_1709160742.xml · derivative · entry 1

Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,816

Underlying: Common Stock · 180,816 shares

Expires 2034-02-13

F1 · shares: This Form 4 amendment is being filed to correct the number of stock appreciation rights awarded to the Reporting Person on February 13, 2024. The original Form 4 filed on February 16, 2024 inadvertently reported the number of stock appreciation rights awarded as 475,831 due to an administrative error.

F2 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.

SEC source: 0001628280-24-004288 · wk-form4_1707776621.xml · nonDerivative · entry 1

DiBiase Mary · CIK 0001880179 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 307,161

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.98 to $1.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

SEC source: 0001628280-24-004263 · wk-form4_1707775417.xml · nonDerivative · entry 1

Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,500

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.97 to $1.07, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-24-004287 · wk-form4_1707776584.xml · nonDerivative · entry 1

Taveras Arthur · CIK 0001830901 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 248,536

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.98 to $1.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

SEC source: 0001628280-24-004266 · wk-form4_1707775482.xml · nonDerivative · entry 1

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 814,746

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.97 to $1.05, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

SEC source: 0001628280-23-036796 · wk-form4_1699046800.xml · nonDerivative · entry 2

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 836,441

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8043 to $0.9454, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award

SEC source: 0001628280-23-036757 · wk-form4_1699044035.xml · nonDerivative · entry 1

DiBiase Mary · CIK 0001880179 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 310,844

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6839 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award

SEC source: 0001628280-23-036758 · wk-form4_1699044122.xml · nonDerivative · entry 1

Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,221

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6835 to $0.7911, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-23-036796 · wk-form4_1699046800.xml · nonDerivative · entry 1

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 876,347

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6835 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award

SEC source: 0001628280-23-036756 · wk-form4_1699043973.xml · nonDerivative · entry 1

Baldry Mark · CIK 0001644137 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,690

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.687 to $0.7927, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award

SEC source: 0001628280-23-036755 · wk-form4_1699043942.xml · nonDerivative · entry 1

Taveras Arthur · CIK 0001830901 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 249,323

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6841 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award

SEC source: 0001628280-23-036459 · wk-form4_1698958524.xml · nonDerivative · entry 1

DiBiase Mary · CIK 0001880179 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 378,539

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.

SEC source: 0001628280-23-036471 · wk-form4_1698959058.xml · nonDerivative · entry 1

Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 310,866

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.

SEC source: 0001628280-23-036466 · wk-form4_1698958841.xml · nonDerivative · entry 1

Baldry Mark · CIK 0001644137 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,947

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.

SEC source: 0001628280-23-036462 · wk-form4_1698958692.xml · nonDerivative · entry 1

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,075,878

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.

SEC source: 0001628280-23-036463 · wk-form4_1698958731.xml · nonDerivative · entry 1

Taveras Arthur · CIK 0001830901 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 317,018

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.

SEC source: 0001628280-23-034579 · wk-form4_1697659344.xml · nonDerivative · entry 1

Woods Keith · CIK 0001996804 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

F1 · shares: Represents a restricted stock units ("RSUs") grant. The RSUs will vest in three equal annual installments commencing on October 16, 2024, subject to the Reporting Person's continued service as a director through each such date.

SEC source: 0001628280-23-032065 · wk-form4_1694549085.xml · nonDerivative · entry 1

DiBiase Mary · CIK 0001880179 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,894

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.22 to $1.255, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Of the shares of common stock reported, 74,046 shares represent restricted stock units.

SEC source: 0001628280-23-031389 · wk-form4_1693944923.xml · derivative · entry 1

Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,250,000

Underlying: Common Stock · 1,250,000 shares

Expires 2033-08-30

F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on August 31, 2024, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001628280-23-030224 · wk-form4_1692734960.xml · nonDerivative · entry 1

WYZGA MICHAEL S · CIK 0001201256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,667

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in two transactions at $1.195 and $1.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price set forth in this footnote.

F2 · balance_after: Of the shares of common stock reported, 48,333 shares represent restricted stock units.